Got­tlieb con­tin­ues to be Trump's lead­ing can­di­date for FDA; Be­yond­Spring com­pletes un­usu­al IPO

→ Scott Got­tlieb is Pres­i­dent Trump’s lead­ing choice for FDA com­mis­sion­er, Bloomberg now re­ports, cit­ing “peo­ple” fa­mil­iar with the mat­ter. Bio­Cen­tu­ry had the scoop in mid-Feb­ru­ary.

→ Be­yond­Spring, a biotech with deep roots in Chi­na, has com­plet­ed an un­usu­al IPO this week. Af­ter ini­tial­ly tar­get­ing an of­fer­ing de­signed to raise $100 mil­lion, the biotech end­ed up sell­ing 174,286 shares at $20 and then ex­e­cut­ed a pri­vate of­fer­ing to in­sid­ers for an­oth­er 2.5 mil­lion shares. The to­tal amount­ed to $54 mil­lion. The com­pa­ny has a can­cer drug in sev­er­al stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER